Premium Phosphosite-Specific 7TM Antibodies
Your Resource for GPCR Research
Select Your Country of Delivery below

CC Chemokine Receptor 6 Antibodies

Close filters
No results were found for the filter!
NEW
Immunohistochemical identification of CC Chemokine Receptor 6 in pancreas
CCR6 (IHC-grade) Chemokine Receptor 6 Antibody
The non-phospho-CCR6 receptor antibody is directed against the distal end of the carboxyl-terminal tail of human CCR6. It can be used to detect total CCR6 receptors in Western blots independent of phosphorylation. The CCR6 antibody can...
$ 375.00 *
Details
NEW
Validation of the CC Chemokine Receptor 6 in transfected HEK293 cells
CCR6 (non-phospho) Chemokine Receptor 6 Antibody
The non-phospho-CCR6 receptor antibody is directed against the distal end of the carboxyl-terminal tail of human CCR6. It can be used to detect total CCR6 receptors in Western blots independent of phosphorylation. The CCR6 antibody can...
$ 375.00 *
Details
NEW
Agonist-induced Serine357 phosphorylation of the Chemokine Receptor 6
pS357-CCR6 (phospho-Chemokine Receptor 6 Antibody)
Serine357 (S357) is a major phosphorylation site of the CCR6 receptor. The pS357-CCR6 antibody detects phosphorylation in response to high- and low-efficacy agonists and after PKC activation. S357 phosphorylation is a key regulator of...
$ 375.00 *
Details
NEW
Agonist-induced Threonine360/Serine361 phosphorylation of the Chemokine Receptor 6
pT360/pS361-CCR6 (phospho-Chemokine Receptor 6...
Threonine360/Serine361 (T360/S361) is a major phosphorylation site of the CCR6 receptor. The pT360/pS361-CCR6 antibody detects phosphorylation in response to high- and low-efficacy agonists and after PKC activation. T360/S361...
$ 375.00 *
Details
NEW
Agonist-induced Threonine363 phosphorylation of the Chemokine Receptor 6
pT363-CCR6 (phospho-Chemokine Receptor 6 Antibody)
Threonine363 (T363) is a major phosphorylation site of the CCR6 receptor. The pT363-CCR6 antibody detects phosphorylation in response to high- and low-efficacy agonists and after PKC activation. T363 phosphorylation is a key regulator of...
$ 375.00 *
Details

C-C chemokine receptor 6 (CCR6), encoded by CCR6, is a class A G protein-coupled receptor whose principal endogenous chemokine ligand is CCL20. It couples predominantly to Gi/o and directs the migration of CCR6-expressing cells along CCL20 gradients. CCR6 is expressed on T helper 17 (Th17) cells, subsets of regulatory and memory T cells, B cells, and immature dendritic cells. At mucosal and epithelial barriers, the CCL20–CCR6 axis helps position immune cells for surveillance and host defense. Inflammatory stimuli can increase epithelial CCL20 production, promoting the recruitment of CCR6-expressing cells to inflamed tissues. CCL20 stimulation can induce CCR6 internalization, reducing receptor availability at the cell surface. Recruitment of pathogenic Th17 cells through this pathway has been implicated in psoriasis and inflammatory bowel disease. The oral CCR6 antagonist IDOR-1117-2520 has entered phase 2 testing for psoriasis, and the small-molecule antagonist PF-07054894 reached phase 1b testing for ulcerative colitis. No CCR6-selective drug is currently approved for therapeutic use. CCR6 desensitization, β-arrestin recruitment and internalization are regulated by phosphorylation of carboxyl-terminal serine357 (pS357-CCR6), threonine360/serine361 (pT360/pS361-CCR6) and threonine363 (pT363-CCR6) residues. This nomenclature refers to the human CCR6. This phosphorylation motif is highly conserved across species and is also present in mice and rats. For more information on CCR6 pharmacology please refer to the IUPHAR database. For further reading refer to:

Bachelerie F, Ben-Baruch A, Burkhardt AM, Combadiere C, Farber JM, Graham GJ, Horuk R, Sparre-Ulrich AH, Locati M, Luster AD, Mantovani A, Matsushima K, Murphy PM, Nibbs R, Nomiyama H, Power CA, Proudfoot AE, Rosenkilde MM, Rot A, Sozzani S, Thelen M, Yoshie O, Zlotnik A. International Union of Basic and Clinical Pharmacology. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors. Pharmacol Rev. 2013 Nov 11;66(1):1-79. doi: 10.1124/pr.113.007724. Print 2014. Review. Erratum in: Pharmacol Rev. 2014 Apr;66(2):467. PubMed PMID: 24218476; PubMed Central PMCID: PMC3880466.

C-C chemokine receptor 6 (CCR6), encoded by CCR6 , is a class A G protein-coupled receptor whose principal endogenous chemokine ligand is CCL20. It couples predominantly to Gi/o and directs... read more »
Close window
CC Chemokine Receptor 6 Antibodies

C-C chemokine receptor 6 (CCR6), encoded by CCR6, is a class A G protein-coupled receptor whose principal endogenous chemokine ligand is CCL20. It couples predominantly to Gi/o and directs the migration of CCR6-expressing cells along CCL20 gradients. CCR6 is expressed on T helper 17 (Th17) cells, subsets of regulatory and memory T cells, B cells, and immature dendritic cells. At mucosal and epithelial barriers, the CCL20–CCR6 axis helps position immune cells for surveillance and host defense. Inflammatory stimuli can increase epithelial CCL20 production, promoting the recruitment of CCR6-expressing cells to inflamed tissues. CCL20 stimulation can induce CCR6 internalization, reducing receptor availability at the cell surface. Recruitment of pathogenic Th17 cells through this pathway has been implicated in psoriasis and inflammatory bowel disease. The oral CCR6 antagonist IDOR-1117-2520 has entered phase 2 testing for psoriasis, and the small-molecule antagonist PF-07054894 reached phase 1b testing for ulcerative colitis. No CCR6-selective drug is currently approved for therapeutic use. CCR6 desensitization, β-arrestin recruitment and internalization are regulated by phosphorylation of carboxyl-terminal serine357 (pS357-CCR6), threonine360/serine361 (pT360/pS361-CCR6) and threonine363 (pT363-CCR6) residues. This nomenclature refers to the human CCR6. This phosphorylation motif is highly conserved across species and is also present in mice and rats. For more information on CCR6 pharmacology please refer to the IUPHAR database. For further reading refer to:

Bachelerie F, Ben-Baruch A, Burkhardt AM, Combadiere C, Farber JM, Graham GJ, Horuk R, Sparre-Ulrich AH, Locati M, Luster AD, Mantovani A, Matsushima K, Murphy PM, Nibbs R, Nomiyama H, Power CA, Proudfoot AE, Rosenkilde MM, Rot A, Sozzani S, Thelen M, Yoshie O, Zlotnik A. International Union of Basic and Clinical Pharmacology. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors. Pharmacol Rev. 2013 Nov 11;66(1):1-79. doi: 10.1124/pr.113.007724. Print 2014. Review. Erratum in: Pharmacol Rev. 2014 Apr;66(2):467. PubMed PMID: 24218476; PubMed Central PMCID: PMC3880466.

Recently viewed